

# Clinical trials of APSAC

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 acute myocardial infarction

Trial	Treatments	Patients	Trials design and methods
<b>APSAC vs control</b>			
<b>APSIM , 1989</b> n=112/119 follow-up: 3 weeks	APSAC 30 U over 5 min versus control (conventional heparin therapy, 5,000 IU in a bolus injection)	patients with a first acute myocardial infarction within 5 h after the onset of symptoms	Parallel groups open France
<b>APSAC vs placebo</b>			
<b>AIMS , 1988</b> n=624/634 follow-up: 1 y	APSAC 30U IV in 5 min versus Placebo	Hommes et femmes, <70 ans	Parallel groups double blind
<b>German Multicenter Trial , 1988</b> n=162/151 follow-up: 28 jours	APSAC 30 units en IV en 5 min, puis hparine en IV (17 U/kg/h) 4 h aprs l'injection d'APSAC versus Hparine 5000 U en bolus en IV, puis 17 U/kg/h	Hommes et femmes, <70 ans	Parallel groups
<b>APSAC vs streptokinase</b>			
<b>ISIS III (SK/APSAC) , 1992</b> n=13780/13773 follow-up: 6 mo	Streptokinase 1.5 MU infused over about 1 h versus anisoylated plasminogen-streptokinase activator complex (APSAC), anistreplase: 30 U over about 3 min	patients within 24 h of the onset of suspected acute myocardial infarction	Plan factoriel 3 (ou 4) *2 double blind International 17 countries
<b>APSAC vs t-PA</b>			
<b>TEAM 3 , 1992</b> n=325 follow-up: 1 months	APSAC, 30 U/2 to 5 min versus rt-PA, 100 mg/3 h,	patient with ST elevation within 4h of the onset of symptoms	double blind

More details and results :

- myocardial revascularization for acute myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q129>
- fibrinolysis for acute myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q260>

## References

### **APSIM, 1989:**

Bassand JP, Machecourt J, Cassagnes J, Anguenot T, Lusson R, Borel E, Peycelon P, Wolf E, Ducellier D Multicenter trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: effects on infarct size and left ventricular function. *J Am Coll Cardiol* 1989 Apr;13:988-97 [2647817]

### **AIMS, 1988:**

Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. AIMS Trial Study Group. *Lancet* 1988 Mar 12;1:545-9 [2894490]

Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. AIMS Trial Study Group. *Lancet* 1990 Feb 24;335:427-31 [1968167]

### **German Multicenter Trial, 1988:**

### **ISIS III (SK/APSAC), 1992:**

ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. *Lancet* 1992;339:753-70 [1347801]

### **TEAM 3, 1992:**

Anderson JL, Becker LC, Sorensen SG, Karagounis LA, Browne KF, Shah PK, Morris DC, Fintel DJ, Mueller HS, Ross AM Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. The TEAM-3 Investigators. *J Am Coll Cardiol* 1992 Oct;20:753-66 [1527286]